Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: MIR22HG acts as a tumor suppressor via TGFβ/SMAD signaling and facilitates immunotherapy in colorectal cancer

Fig. 7

Rational combinational therapy of MIR22HG and aPD-L1 in CRC. a, Box plots showing the distribution of mutation burden, MHC, immune and CYT scores in patients with MIR22HG low and high expression. b, C57B/6 mice were orthotopically xenografted with MC38 injection and treated with aPD-L1 or IgG every 3 days. c, Representative images of tumors treated with IgG + MIR22HG or aPD-L1 + MIR22HG. d and e, The tumor weight and volume of mice treated with IgG + MIR22HG or aPD-L1 + MIR22HG. f, The upper panel showing tumor images of C57B/6 mice. Bottom panel shows the total flux of mice after injections in different groups. g, Kaplan-Meier survival curve of C57B/6 mice is shown

Back to article page

Molecular Cancer

ISSN: 1476-4598